(Boursier.com) — NANOBIOTIX, a clinical-stage and late-stage biotechnology company developing innovative physics-based therapeutic approaches to revolutionize the benefits of treatments for cancer patients, today announces the availability of the admission prospectus approved by the Financial Markets Authority under number 23-461, on November 3, 2023, as part of two capital increases for a total gross amount of approximately $50 million as well as the partial exercise of the over-allotment option granted to the guarantor banks by the Company for an additional amount of approximately $3.6 million.
The first capital increase was subscribed for a total gross amount of approximately $30 million by qualified investors. This capital increase was increased by an additional amount of approximately $3.6 million, following the partial exercise of the over-allotment option.
The second capital increase was subscribed by Johnson & Johnson Innovation – JJDC Inc for a total gross amount of approximately $20.2 million.
Pursuant to the share subscription agreement entered into with the Company, JJDC has committed to subscribe a total amount of $25 million. To comply with the rules applicable to the control of foreign investments in force in France, this amount was reduced for an initial subscription by JJDC of approximately 20.2 million dollars, the capital increase for the balance of approximately 4 .8 million dollars will be subscribed by JJDC immediately and subject to the prior approval of the Ministry of Economy and Finance. This subscription would bring the total gross amount raised by Nanobiotix to $55 million, excluding exercise of the over-allotment option.
©2023 Boursier.com